Johnson & Johnson raised its full-year financial outlook Wednesday after reporting stronger-than-expected second-quarter results, putting the healthcare giant on pace to surpass $100 billion in annual revenue for the first time in its 140-year history.

The company reported second-quarter sales of $25.3 billion, an increase of 6.6% from a year earlier, while adjusted earnings came in at $2.90 per share, topping Wall Street expectations. Chairman and Chief Executive Officer Joaquin Duato said the results reflected continued strength across the company’s pharmaceutical and medical technology businesses despite growing competition for one of its largest medicines.

For investors, the quarter reinforced a central theme surrounding Johnson & Johnson: the company is proving it can continue growing even as STELARA, one of its biggest revenue generators, faces biosimilar competition.

Revenue Nears Historic Milestone

Johnson & Johnson increased its 2026 sales guidance to between $100.8 billion and $101.4 billion, making it likely the company will exceed $100 billion in annual revenue for the first time.

The revised outlook also included higher earnings guidance, with adjusted earnings now expected between $11.60 and $11.75 per share, above previous forecasts and ahead of Wall Street consensus estimates.

Crossing the $100 billion threshold would represent a historic milestone for one of the world’s largest healthcare companies and further strengthen its position among the biggest publicly traded corporations in the United States.

Pharmaceutical Pipeline Offsets Patent Pressure

The quarter demonstrated Johnson & Johnson’s strategy of replacing aging blockbuster medicines with newer therapies.

While STELARA continues losing exclusivity to lower-cost biosimilars, growth from newer medicines and the company’s MedTech division more than offset those headwinds.

Excluding STELARA, management said the Innovative Medicine business delivered double-digit growth during the quarter.

The company also highlighted several regulatory approvals and positive clinical developments, including expanded uses for TREMFYA, CAPLYTA, and the THERMOCOOL SMARTTOUCH SF platform, along with encouraging oncology data involving RYBREVANT FASPRO, TALVEY, and DARZALEX FASPRO.

Those products are expected to become increasingly important as Johnson & Johnson continues refreshing its pharmaceutical portfolio.

Medical Technology Remains a Growth Engine

Johnson & Johnson’s MedTech division continued benefiting from steady demand for surgical equipment, orthopedic products, cardiovascular technologies, and hospital procedures.

Healthcare systems have largely normalized following pandemic-related disruptions, allowing procedure volumes to recover while supporting demand for medical devices.

Management also said a planned acquisition will strengthen the company’s next-generation oncology platform by adding new antibody technology.

Orthopedics Separation Still Planned

Chief Financial Officer Joe Wolk reaffirmed that Johnson & Johnson remains on track to separate its DePuy Synthes orthopedic business around mid-2027.

The move is intended to create a more focused medical technology organization while allowing Johnson & Johnson to continue investing in higher-growth therapeutic areas.

Investors continue watching the planned separation because of its potential impact on the company’s future growth profile and capital allocation strategy.

Why the Quarter Matters

Johnson & Johnson’s results illustrate how large pharmaceutical companies must continually replace aging blockbuster medicines with new therapies to sustain long-term growth.

This quarter suggests that strategy is working.

The company’s ability to raise both revenue and earnings guidance despite increasing biosimilar competition provides additional confidence that its pipeline is beginning to offset expected declines from older products.

For New Jersey, where Johnson & Johnson has been headquartered since 1886, the milestone carries broader economic significance beyond shareholders. The company remains one of the state’s largest employers and supports thousands of jobs across research, manufacturing, healthcare, logistics, and corporate operations.

If current guidance holds, Johnson & Johnson will become one of only a handful of American companies generating more than $100 billion in annual revenue—a milestone reflecting both the scale of its global healthcare franchise and its continued investment in pharmaceuticals and medical technology.

JBizNews Desk | New Brunswick

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.